Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | ITGB2 | P05107 | 9/20 | 0.57 |
| ▸ | ICAM1 | P05362 | 9/20 | 0.57 |
| ▸ | ITGAL | P20701 | 9/20 | 0.57 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1020786 | 1.00 | HDAC1 (0.61) | HDAC1HDAC8HDAC6ITGB2ICAM1 | |
| SCHEMBL29381982 | 1.00 | HDAC1 (0.61) | HDAC1HDAC8HDAC6ITGB2ICAM1 | |
| SCHEMBL5019656 | 1.00 | HDAC1 (0.61) | HDAC1HDAC8HDAC6ITGB2ICAM1 | |
| Hydrochloric Acid SCHEMBL29478485 | 0.99 | HDAC6 (0.60) | HDAC1HDAC8HDAC6ITGB2ICAM1 | |
| SCHEMBL23666454 | 0.93 | HDAC1 (0.65) | HDAC1HDAC8HDAC6ITGB2ICAM1 | |
| SCHEMBL17132276 | 0.91 | KMT2A (0.51) | HDAC1HDAC8HDAC6ITGB2ICAM1 | |
| SCHEMBL6763024 | 0.87 | HDAC1 (0.67) | HDAC1HDAC8HDAC6ITGB2ICAM1 | |
| SCHEMBL6763018 | 0.87 | HDAC1 (0.67) | HDAC1HDAC8HDAC6ITGB2ICAM1 | |
| SCHEMBL6759553 | 0.87 | ITGB2 (0.74) | HDAC1HDAC8HDAC6ITGB2ICAM1 | |
| SCHEMBL6759557 | 0.87 | ITGB2 (0.74) | HDAC1HDAC8HDAC6ITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211702-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2022-07-07 | — | — | US | claimed |
| EP-3952992-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | Mayo Foundation for Medical Education and Research (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2020210707-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2020-10-15 | — | — | WO | claimed |
| US-20110159474-A1 | SOLUTIONS FOR PERFUSING AND PRESERVING ORGANS AND TISSUES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-30 | — | — | US | claimed |
| EP-2154956-A2 | SOLUTIONS FOR PERFUSING AND PRESERVING ORGANS AND TISSUES | Bayer Schering Pharma AG (DE) | 2010-02-24 | — | — | EP | claimed |
| WO-2008148474-A2 | SOLUTIONS FOR PERFUSING AND PRESERVING ORGANS AND TISSUES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-11 | — | — | WO | claimed |
| US-20050181066-A1 | Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | US | claimed |
| WO-2005042022-A2 | COMBINATION OF AN ACTIVATOR OF SOLUBLEGUANYLATE CYCLASE AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST | PFIZER LIMITED (GB) | 2005-05-12 | — | — | WO | claimed |
| US-20050059660-A1 | activators of soluble guanylate cyclase, and inhibitors of angiotensin converting enzyme such as benazepril; treatment of cardiovascular or metabolic disorders | PHARMACIA & UPJOHN COMPANY | 2005-03-17 | — | — | US | claimed |
| WO-2005011727-A1 | COMBINATION OF AN ACTIVATOR OF SOLUBLE GUANYLATE CYCLASE AND AN ACE-INHIBITOR FOR THE TREATMENT OF A CARDIOVASCULAR OR METABOLIC DISORDER | PFIZER LIMITED (GB) | 2005-02-10 | — | — | WO | claimed |
| EP-1501605-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA Pharma AG (DE) | 2005-02-02 | — | — | EP | claimed |
| WO-2003090870-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA PHARMA AG (DE) | 2003-11-06 | — | — | WO | claimed |
| US-12465605-B2 | Methods and materials for gender-dependent treatment of cardiovascular dysfunction | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-11-11 | — | — | US | disclosed |
| US-20220211702-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2022-07-07 | — | — | US | disclosed |
| EP-3952992-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | Mayo Foundation for Medical Education and Research (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2020210707-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2020-10-15 | — | — | WO | disclosed |
| US-20050059660-A1 | activators of soluble guanylate cyclase, and inhibitors of angiotensin converting enzyme such as benazepril; treatment of cardiovascular or metabolic disorders | PHARMACIA & UPJOHN COMPANY | 2005-03-17 | — | — | US | disclosed |
| WO-2005011727-A1 | COMBINATION OF AN ACTIVATOR OF SOLUBLE GUANYLATE CYCLASE AND AN ACE-INHIBITOR FOR THE TREATMENT OF A CARDIOVASCULAR OR METABOLIC DISORDER | PFIZER LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| EP-1501605-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA Pharma AG (DE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003090870-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA PHARMA AG (DE) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110159474-A1 | SOLUTIONS FOR PERFUSING AND PRESERVING ORGANS AND TISSUES | GUCY1A1, GUCY1A2, PDE3B | HDAC1 4686/4885HDAC8 4583/4885HDAC6 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.